Hsiri Therapeutics

Executive Summary

Hsiri Therapeutics is a private biotechnology company based in Cambridge, MA, dedicated to discovering and developing novel small-molecule therapies for infections caused by drug-resistant bacteria and fungi. Founded in 2020, the company’s research originates from academic institutions including the University of Notre Dame and Montana State University, with a core focus on mycobacterial diseases such as tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections, as well as other resistant bacterial and fungal pathogens. The global rise of antimicrobial resistance (AMR) represents a critical unmet medical need, and Hsiri’s efforts to target resistant pathogens could address significant gaps in current treatment paradigms. While the company is still in its early stages and has not disclosed specific pipeline candidates or funding rounds, its academic roots and focus on high-priority pathogens position it as a potential player in the AMR space. Continued progress will likely depend on securing additional financing and advancing lead candidates into preclinical development.

Upcoming Catalysts (preview)

• Q4 2026Completion of Lead Optimization for Lead Candidate60% success
• H1 2027Initiation of IND-Enabling Studies40% success
• Q2 2027Series A Financing Round70% success